Clinical Trial Update: A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for ex vivo administration of iCM012 to improve kidney graft function in donation-after-circulatory-death recipients. Phase 2/3, not yet r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Kidney Transplantation

Drugs mentioned

• iCM012

Snippet

Sponsor: iCoat Medical AB | Conditions: Ischemia-reperfusion Injury, Kidney Transplant; Complications | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING